Calculus partially Exits Scancell

Calculus Capital has successfully exited its investors’ shares in Scancell – a biotech company which develops novel immunotherapies for the treatment of cancer, based upon its ImmunoBody® and Moditope® technology platforms.

Calculus sold the shares in Scancell through a placing in the market, delivering yet another great return to our investors.

Fund 8: In price per share: 4.5p
Average out price per share: 36.9p
Scancell was founded in 1997 as a spin-out from the University of Nottingham. In September 2008 Scancell became a public company following admission to the UK PLUS stock exchange and subsequently moved to AIM in July 2010.

Scancell’s first ImmunoBody®, SCIB1, is being developed for the treatment of melanoma and is in Phase II clinical trials. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism – the immune system. Scanell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

Calculus continues to hold investments in Scancell for investors in later funds.